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Meeting Report
OXYGEN 2011
Max Gassmann
Oxygen 2011 was a combined research conferenceworkshop and training school of the European Hypox-
iaNet COST Action TD0901, which took place January 8 to 12,
2011, in Davos, Switzerland. Oxygen 2011 focused on the
molecular mechanisms of oxygen sensing and the physiologic
and pathologic effects of hypoxia on cells, organs, and whole-
body functions. Apart from classical seminar sessions, two
valuable and unique events were presented at this meeting.
The first was a training school in which methodologies of
hypoxia cell culture were presented and discussed by aca-
demic researchers and scientists from companies creating
cutting-edge equipment for hypoxia research. The second
novel session was a workshop designed to bring together
academic and commercial scientists, students, and junior re-
searchers to share their knowledge of prolyl hydroxylase (PHD)
inhibition and discuss specifics of how to promote the devel-
opment of PHD inhibitors for use in basic and clinical sciences.
Professor Kari Alitalo delivered the keynote address, in
which he presented the role of hypoxia in angiogenesis by
activation of the complex vascular endothelial growth factors
(VEGF) pathways and the consequences of this activation in
cardiovascular development and lymphangiogenesis. The
seminar provided many insights into specific subjects to be
further discussed at the meeting, including oxygen sensing,
the role of hypoxia in metabolism, cancer, angiogenesis, and
the potential clinical effect of specific PHD inhibitors on var-
ious hypoxia-mediated pathways. Appropriately, the first
day beganwith oxygen sensing, starting off with comparative
aspects and moving on to focus on mammalian mechanisms,
as the majority of attendees research mammalian responses to
hypoxia. Unpublished data were included in most talks, re-
vealing important advances in the understanding of the
control of hypoxia-inducible transcription factors 1 and 2
(HIF1, HIF2), mechanisms allowing HIFs to have discrete and
distinct actions, temporal differences in the molecular re-
sponse to hypoxia, and the role of mitochondria in oxygen
sensing. These topics led naturally into the sessions on hyp-
oxia and metabolism, in which new data on hypoxia’s role in
metabolism in a variety of pathologies, including obesity,
renal cancer, and pulmonary fibrosis, were presented. The
final session of the day delivered exciting new data revealing
greater potential for discrete control of HIF(s) activation that
may be exploited in therapeutic strategies, including speci-
ficity of PHDs, HIF phosphorylation, and reactive oxygen
species. This session stimulated keen interest in the workshop
on PHD-inhibiting drugs held later in the meeting.
The second day began with sessions focusing on the role of
hypoxia in disease, including skeletal muscle injury, central
nervous system injury, including a fascinating new in vitro,
three-dimensional, multicellular model of the blood–brain
barrier, and hypoxic activation of the lymphocytic chor-
iomeningitis virus (LCMV), which has significant implica-
tions for kidney transplants and frequent miscarriage. A
fascinating set of data were presented in which the sensitivity
and mechanisms of HIF2 activation and subsequent erythro-
poietin (EPO) productionwere implicated in the development
of renal clear cell carcinoma. This led to a session on EPO, EPO
receptor (EPOR), and erythrocytosis. The genetic origins of
erythrocytosis in human disease revealed mutations in Von
Hippel–Lindau (VHL), PHD2, and HIF2A genes, and various
laboratory-induced mutations in EPOR revealed that the lo-
cation of EPOR (cell membrane or cytosolic) can be manipu-
lated during hypoxia, that GATA4 is instrumental in EPOR
transcription in the heart, and that CITED2 is crucial for me-
diating hematopoietic stem cell fates during hypoxia.
The seminar series continued on the third day beginning
with the effects of high altitude on exercise performance. This
began with a novel seminar title, a quote adapted from one of
themost famous early hypoxia–altitude researchers, Peruvian
Carlos Monge: ‘‘Humans are a sea level design.’’ The role of
erythrocytosis and the adaptation of human populations to
high altitude were explored with new data suggesting that
manipulation of iron concentrations may alter human re-
sponse to chronic hypoxia. This was followed by the presen-
tation of invasive and unique human studies that expanded
on the hypothesis that iron stores may contribute to successful
or failed adaptation to chronic hypoxia. In the following ses-
sion on lymphangiogenesis and hypoxia, world-class inves-
tigators presented unpublished data implying that HIF1 and
HIF2 have opposite effects on nitric oxide production, thus
altering vascular response to hypoxia; hypoxic induction of
hemeoxygenase 1 (HO1) mediates angiogenesis and prolif-
eration during hypoxia, thus mediating metastasis; and the
hypoxia—VEGF—matrix metalloproteinase (MMP9) path-
way may mediate blood–brain barrier permeability during
hypoxia.
An afternoon session was dedicated to short presentations
by junior investigators and graduate students that further
highlighted the ongoing research in numerous areas of hyp-
oxia science and the role of the younger generation in hypoxic
research. Daily poster sessions provided another platform for
the presentation of novel complementary data, in addition to
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that presented in seminars. There was lively discussion and
high attendance at these sessions, which generated consider-
able opportunities for collaboration between laboratories
throughout Europe and the world.
Further activities included a training school and workshop
that provided novel forums for a number of topics. The
training school focused on hypoxic cell culture and included
presentations by both academic and commercial scientists. It
began with a very focused review by Roland Wenger on the
gas laws and the importance of fully understanding and
considering the physics of these principles when designing
experiments using hypoxic cell culture. This was followed by
presentations from scientists representing companies that
make hypoxic cell culture hoods and oxygen- monitoring
devices; they shared valuable information about important
considerations when selecting and using equipment special-
ized for hypoxic cell culture. Their experience with a large
variety of research needs gave participants new and critical
insights into various aspects of hypoxic cell culture that are
often ignored or overlooked. The knowledge gained from this
training school will invariably improve the quality of exper-
iments performed by participants and their colleagues, thus
greatly improving the quality of the data resulting from these
numerous international laboratories and significantly en-
hancing the field of hypoxia biomedical research. The com-
panies and sponsors contributing to this endeavor were
impressed with the attendance at these sessions and the in-
terest in their presentations. This resulted in a strong interest
in supporting such conferences in the future.
The workshop focused on PHD-inhibiting drugs and was
held as a discussion forum. Initial presentations by academic
and commercial scientists were followed by a round-table
discussion on how to best forge links between the academic
and pharmaceutical industry. The consensus at the conclusion
of this workshop was that it is not only groundbreaking dis-
coveries that provide great insight for the pharmaceutical
industry to expand on, with the goal of developing better and
more specific PHD inhibitors. Further, pharmaceutical com-
panies would like to forge closer ties with all academic re-
searchers, not just senior scientists, as they believe that very
important basic science data are coming from their laborato-
ries. There was general agreement that such workshops
would be highly attended at other meetings if they were
available. The overall primary consensus was that academic
and industrial scientists alike are united in their desire to
create a product useful for hypoxia-oriented research and
medicine.
Overall, this research conference provided an excellent
opportunity for scientists from a number of diverse fields,
including cancer, immune disorders, inflammation, pulmo-
nary disorders, adaptation to high altitude, fetal develop-
ment, and cardiovascular disease, to interact and present data
on a very focused and critical part of their research: hypoxia.
Speakers revealed an unprecedented amount of unpublished
data, creating riveting presentations. The additional and no-
vel opportunity to interact closely with industrial scientists in
the training school and workshop allowed, for the first time,
the chance for both groups to hear from each other in a forum
inviting discussion and learning in an open and low-pressure
environment. It is certain that many future new investigations
and collaborations will develop from this impressive event.
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